Platinum Industries Signs CAREGEN Korglutide Deal; Shares Rise 0.83%

Mumbai, September 29: Platinum Industries Limited said its subsidiary Rivadu Lifesciences Private Limited has entered into an exclusive Sale/Purchase Agreement with South Korea-based CAREGEN Co., Ltd. for India-related sales of Korglutide health functional food products.

Rivadu Lifesciences Enters Exclusive India Agreement

Rivadu Lifesciences, a subsidiary of Platinum Industries, signed the agreement with CAREGEN on September 28, 2026. The arrangement gives Rivadu exclusive rights for the sale and purchase of CAREGEN’s Korglutide health functional food finished products in India.

The agreement also sets out plans for an Indian partnership and prospects for establishing manufacturing operations in the country. According to the exchange filing, CAREGEN is not related to Platinum Industries’ promoter or promoter group, and the transaction does not fall under the related-party transaction framework.

Stock Market Snapshot

The Platinum Industries share price stood at ₹207.62 as of 12:03:41 PM IST on September 29, 2026, according to the market data provided.

The stock was up ₹1.71, or 0.83%, at the time. Shares moved higher through the late morning after trading below ₹205 during the earlier part of the session.

Agreement Covers Korglutide Products In India

The agreement covers CAREGEN’s Korglutide-branded health functional food finished products for the Indian market. Rivadu Lifesciences will act as the company’s subsidiary for the arrangement in India.

The disclosure also points to potential manufacturing activity in India, although the filing does not provide details such as investment size, production capacity or a specific timeline for setting up a manufacturing facility.

No shareholding in CAREGEN is involved under the agreement, and no equity securities are being issued as part of the arrangement.

Platinum Industries Expands Into Health Functional Foods

The agreement gives Platinum Industries a route into the health functional food segment through its subsidiary, alongside its existing business operations.

For Rivadu Lifesciences, the arrangement creates an exclusive India-focused commercial relationship with CAREGEN and could also support the company’s plans around local manufacturing, subject to the development of the proposed operations.

Conclusion

Platinum Industries’ subsidiary Rivadu Lifesciences has entered an exclusive Sale/Purchase Agreement with CAREGEN for Korglutide health functional food products in India.

The agreement includes exclusive India partnership rights and prospects for establishing manufacturing operations in the country. The Platinum Industries share price stood at ₹207.62 as of 12:03:41 PM IST on September 29, 2026, up ₹1.71 or 0.83%.

Source:

• https://www.nseindia.com/get-quote/equity/PLATIND/Platinum-Industries-Limited
• https://nsearchives.nseindia.com/corporate/PLATINUM_29092026113612_Reg_30__Intimation_about_Exclusive_Agreement.pdf